Search Medical Condition
Please enter condition
Please choose location

Uterine Cancer Clinical Trials

A listing of Uterine Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (339) clinical trials

Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel in Combination With Paclitaxel or in Combination With Anastrozole

This is an open-label Phase 1b, dose escalation study of oral ARQ 092 administered in combination with carboplatin plus paclitaxel (Carboplatin Plus Paclitaxel Arm) or in combination with paclitaxel alone (Paclitaxel Arm) in subjects with advanced, inoperable metastatic and/or recurrent solid tumors, or in combination with anastrozole (Anastrozole Arm) in ...

Phase

Preoperative Olaparib Endometrial Carcinoma Study (POLEN)

The main objective of the present proposal study is to assess the biological consequences of PARP inhibition in type I primary EC, in patients who receive therapy with AZD2281 during the period of time between diagnosis and surgery. This is a phase 0 trial or "Exploratory Investigational New Drug" study, ...

Phase N/A

A Trial of Comparing the Pathology Status of Lymphoseek -Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single dose of 50 g Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.

Phase

Pembro/Carbo/Taxol in Endometrial Cancer

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: To ensure the safety of this combination treatment, an initial safety run-in will be conducted for the first 6 subjects. This initial cohort of 6 subjects will be enrolled and treated with standard doses as described below. Based on toxicity analysis of ...

Phase

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial Ovarian or Cervical Cancer (AL3818-US-001)

This is a Phase 1b/2a study to evaluate the safety, pharmacokinetics and efficacy of 21-day cycles of AL3818 therapy. The study is divided into two parts. Part 1 (Phase 1b) will evaluate the dose limiting toxicity (DLT) and general safety during the first 21-day cycle of Al3818 therapy and to ...

Phase

Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial Ovarian Fallopian Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

This trial is a Phase 1b/2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy such as carboplatin plus paclitaxel, concurrently and continued as a maintenance therapy for up to 12 months, in subjects with recurrent or metastatic endometrial, ovarian, fallopian, primary peritoneal, ...

Phase

Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

This is an open-label, single center, intra-patient safety and comparison study of Lymphoseek (Technetium Tc 99m Tilmanocept) and vital blue dye for the detection of lymph nodes in patients with endometrial cancer that are undergoing a lymph node dissection as part of their standard medical care. The day before surgery, ...

Phase

DNA Methylation Biomarkers for Cervical Cancer Screening

The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.

Phase N/A

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD or Pembrolizumab in Adults With FRa + Adv. EOC Primary Peritoneal Fallopian Tube or Endometrial Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen in hormone receptor positive, HER2 negative metastatic breast cancer patients who have progressed after prior endocrine treatment .Description of toxicity profile, severity and frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To ...

Phase